

(B) Amendments to the claims

Claims 1-10 (cancelled)

11. (previously added) A method for the prevention or treatment of angiogenesis in a patient in need of such treatment, which comprises intra-arterially administering an effective embolism-causing amount of a bisphosphonate compound, or a pharmaceutically acceptable salt thereof or a hydrate thereof, to the patient.
12. (currently amended) A method according to claim 1 for the treatment of angiogenesis associated with inflammation, myocardial ischemia, rheumatoid arthritis, osteoarthritis and tumour formation.
13. (currently amended) A method according to claim ~~4~~11 in which the bisphosphonate is selected from the following compounds or a pharmaceutically acceptable salt thereof, or any hydrate thereof: 3-amino-1-hydroxypropane-1,1-diphosphonic acid, 3-(N,N-dimethylamino)-1-hydroxypropane-1,1-diphosphonic acid, 4 amino-1-hydroxybutane-1,1-diphosphonic acid, 1-hydroxy-ethidene-bisphosphonic acid, 1-hydroxy-3-(methylpentylamino)-propylidene-bisphosphonic acid, ibandronic acid, 6-amino-1-hydroxyhexane-1,1-diphosphonic acid, 3-(N-methyl-N-n-pentylamino)-1-hydroxypropane-1, 1-diphosphonic acid, 1-hydroxy-2-(imidazol-1-yl)ethane-1,1-diphosphonic acid, 1-hydroxy-2-(3-pyridyl)ethane-1,1-diphosphonic acid, 1-(4-chlorophenylthio) methane-1,1-diphosphonic acid, 3[N-(2-phenylthioethyl)-N-methylamino]-1-hydroxypropane-1,1-diphosphonic acid, 1-hydroxy-3-(pyrrolidin-1-yl)propane-1,1-diphosphonic acid, 1-(N-phenylaminothiocarbonyl)methane-1,1-diphosphonic acid, 5-benzoyl-3,4-dihydro-2H-pyrazole-3,3-diphosphonic acid tetraethyl ester, 1-hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)ethane-1,1-diphosphonic acid and 1,1-dichloromethane-1,1-diphosphonic acid.
14. (currently amended) A method according to claim ~~4~~11 wherein the bisphosphonate is pamidronic acid, or a pharmaceutically acceptable salt thereof, or any hydrate thereof.
15. (currently amended) A method according to claim ~~11~~4 wherein the bisphosphonate is zoledronic acid, or a pharmaceutically acceptable salt thereof, or any hydrate thereof.

16. (previously added) A method of inhibiting basic fibroblast growth factor induced angiogenesis, which comprises administering an effective amount of zoledronic acid or a pharmaceutically acceptable salt or a hydrate thereof.

17. (previously added) A method of inhibiting angiogenesis, which comprises administering an effective amount of a bisphosphonate compound or a pharmaceutically acceptable salt thereof or a hydrate thereof in combination with a vascular endothelial growth factor inhibitor.

18. (previously added) A method of claim 17 wherein the bisphosphonate compound is zoledronic acid or a pharmaceutically acceptable salt thereof or a hydrate thereof.